NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
Don't have an account? Register
ADVERTISEMENT
ADVERTISEMENT
Obesity is a complex chronic disease which needs multiple treatments and a multidisciplinary approach, delegates attending the Irish Society of Gastroenterology Winter Meeting 2023 heard, during a dedicated symposium on the modern approach to obesity and bariatric surgery
Noted obesity expert Prof Carel le Roux, Professor of Metabolic Medicine, University College Dublin, discussed the evolution of scientific evidence on obesity as a disease and the need to treat it like any other condition, such as cancer or diabetes. He described obesity as a neurological disease and a “fundamental biological dysregulation of where your [fat mass] thermostat is set”.
“The disease of obesity causes people to over-eat and if you treat it, people will eat less.”
Prof le Roux pointed to the overall impact of obesity on the development/exacerbation of a number of health conditions, such as type 2 diabetes, cardiovascular disease, infertility, liver disease, sleep apnoea, gout and joint issues. Treating the underlying condition, ie, obesity, can help dramatically improve/cure many of these associated conditions.
There are now a range of successful and evidence-based treatments for obesity, including bariatric surgery and medications, such as the GLP-1 inhibitors; however, treatment and access remain a challenge, Prof le Roux said. He added while diet and lifestyle offer benefits for some people, and should continue to be advised, they clearly do not work for the majority of those with obesity.
The data also show that the long-term benefit of anti-obesity medications, such as GLP-1 inhibitors, requires continued treatment, as once they are stopped most people regain the weight, Prof le Roux stated. He questioned reimbursement regimes that put a time cut-off on access to these medications.
Concluding, Prof le Roux said the future of obesity care will include chronic treatment “aimed at health gain not weight loss”, recognising the different subtypes of the disease, and the need for tailored treatments for each, and “not blaming our patients for their disease or if they don’t respond”.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
The Irish Osteoporosis Society Annual Medical Conference will hear from experts about the latest evidence and...
A recent conference in Dublin discussed the impact that climate change and the environment are having...
ADVERTISEMENT
There is a lot of publicity given to the Volkswagen Golf, which is celebrating 50 years...
As older doctors retire, a new generation has arrived with different professional and personal priorities. Around...
Catherine Reily examines the growing pressures in laboratory medicine and the potential solutions,with a special focus...
The highlight of this year’s Irish Society for Rheumatology (ISR) Autumn Meeting was undoubtedly the...
ADVERTISEMENT
ADVERTISEMENT
Leave a Reply
You must be logged in to post a comment.